BRIEF published on 11/27/2024 at 18:05, 1 year 2 months ago ABIVAX: Update of Share Capital and Voting Rights Euronext Paris Share Capital Voting Rights Abivax Financial Transparency
BRIEF published on 11/19/2024 at 22:35, 1 year 2 months ago Abivax Launches ATM Program on Nasdaq Common Shares Biotechnology Funding Nasdaq ATM Program
PRESS RELEASE published on 11/19/2024 at 22:30, 1 year 2 months ago Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax establishes an At-the-Market (ATM) Program on Nasdaq, allowing issuance and sale of ordinary shares to raise up to $150 million. Implementation involves Piper Sandler & Co. as sales agent Ordinary Shares Abivax Nasdaq ATM Program Piper Sandler
BRIEF published on 11/14/2024 at 22:06, 1 year 2 months ago Abivax Releases Q3 2024 Financial Results Financial Results Biotechnology Abivax Ulcerative Colitis Q3 2024
PRESS RELEASE published on 11/14/2024 at 22:01, 1 year 2 months ago Abivax presents third quarter 2024 key financial information Abivax presents key financial information for the third quarter of 2024. The company announced updates on operational goals and debt status. Details on Abivax's cash and principal debt outstanding are provided Financial Information Abivax Quarter Results Clinical-stage Biotechnology Debt Status
BRIEF published on 11/13/2024 at 22:06, 1 year 2 months ago Abivax Appoints Mark Stenhouse as Observer and Strategic Advisor Biotechnology Abivax Obefazimod Appointment Mark Stenhouse
PRESS RELEASE published on 11/13/2024 at 22:01, 1 year 2 months ago Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax Abivax appoints Mark Stenhouse, former Prometheus COO, as Board Observer & Advisor, bringing extensive biopharma experience to support clinical therapeutics development Abivax Mark Stenhouse Prometheus Board Observer Clinical Therapeutics
BRIEF published on 10/11/2024 at 18:05, 1 year 3 months ago ABIVAX terminates its liquidity contract Liquidity Contract Biotechnology Termination Trading Abivax
BRIEF published on 10/11/2024 at 18:05, 1 year 3 months ago ABIVAX: Number of Shares and Voting Rights as of September 30, 2024 Euronext Paris Share Capital Voting Rights AMF Abivax
PRESS RELEASE published on 10/11/2024 at 18:00, 1 year 3 months ago ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement. Abivax terminates liquidity contract with TSAF SA, releasing details of assets in the account and transactions. Company focuses on developing therapies for chronic inflammatory diseases Liquidity Contract Termination Abivax Therapeutics Immune Response
Published on 01/31/2026 at 03:15, 7 hours 6 minutes ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 8 hours 1 minute ago Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 8 hours 41 minutes ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 11 hours 21 minutes ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 02:45, 7 hours 35 minutes ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 12 hours 21 minutes ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 14 hours 10 minutes ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 14 hours 11 minutes ago Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 14 hours 13 minutes ago Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 17:45, 16 hours 36 minutes ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 1 day 16 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 16 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 16 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
